Similarly, PREDICT v1.3 performed well in Malaysian patients [67], but less accurately in patients with BRCA1 mutations [63], patients aged 40 years or less [67], and those with ER positive and HER2 negative tumours [68], and inconsistently in elderly patients [67, 69]. This evidence concerns the gene ERBB2 and neoplasm.